At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 36 enrolled
Drug / intervention
Apremilastdrug
Likely dose
Apremilast 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single-Dose Study to Evaluate the Effects of Age and Sex on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Apremilast for Healthy Volunteer. Completed, enrolled 36 participants across 2 sites.
Detailed Summary
The purpose of the study is to evaluate the effects of age and sex on the pharmacokinetics and safety of a single oral dose of 30 mg apremilast in healthy adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteer
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2012
Primary CompletionMar 2012
Study CompletionApr 2012
First PostedJul 2012
TodayJul 2026
First PostedJul 6, 2012
Enrollment StartFeb 1, 2012
Primary CompletionMar 1, 2012
Study CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 14.0 years ago
Interventions
Apremilastdrug
One oral 30 mg dose of apremilast